In this photo Nov.30, 2020 file photo the logo of French drug maker Sanofi is picture at the company's headquarters, in Paris. Sanofi and GlaxoSmithKline's potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials, boosting optimism that the shot may join the fight against the pandemic by the end of this year. (AP Photo/Thibault Camus, File)
PARIS (AP) — Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials, boosting optimism the shot may join the fight against the pandemic this year.
After two doses of the vaccine candidate, participants showed neutralizing antibodies in line with those found in people who had recovered from the disease, according to results of the Phase 2 trial released Monday. The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.
Regulators have already authorized a number of COVID-19 vaccines, though experts say more are needed as public health authorities around the world race to vaccinate their residents amid a pandemic that has already killed more than 3.3 million people and caused economic havoc.
The Sanofi-GSK vaccine was an important part of the European Union's vaccination strategy, and had notably been championed by French President Emmanuel Macron's government. But researchers had to reformulate it after early testing produced an inadequate immune response in older people.
The Sanofi-GSK candidate joins about a dozen vaccines now undergoing late-stage trials. The companies plan to produce up to 1 billion doses annually, and they have signed agreements to supply the U.S., Canada and developing countries, too. Public health experts say several vaccines will be needed to end the pandemic, because of the challenges in rapidly producing and distributing enough doses to vaccinate billions of people.
“We know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures increases,” said Thomas Triomphe, head of Sanofi’s vaccines unit.
The results released Monday were from a Phase 2 trial involving 722 volunteers aged 18 to 95 who were recruited in the U.S. and Honduras.
The late-stage trial will involve about 37,000 participants from countries around the world, the companies said.
Featured Article: How to Invest in the Dividend Aristocrat Index7 Electric Vehicle (EV) Stocks That Are Ready to Rebound
The electric vehicle (EV) sector was nearly as frothy as the “pandemic stocks” in 2020. It wasn’t that the EV sector was dormant during the Trump administration.
But, as the saying goes, elections have consequences. And Wall Street understands they can make money in any administration. And as a bet that Joe Biden would win the presidency, electric vehicle stocks soared.
For starters, the Biden administration has already said it will prioritize climate change like no administration ever has. And one way they are going to do that is to incentivize the production and purchase of electric vehicles.
And to take advantage of this shift towards electric vehicle stocks, many private companies raced to get in on the action. The preferred way for many of these companies to go public was via a Special Purpose Acquisition Company (SPAC). A SPAC is basically a shortcut to the traditional IPO process.
However, what goes up frequently goes down and since late February, EV stocks have been getting battered. But this is creating an opportunity because the electric vehicle is still supposed to see exceptional growth over the next five years.
To help you take advantage of this we’ve created this special presentation that includes seven stocks that appear to be ready to take the next leg up.
View the "7 Electric Vehicle (EV) Stocks That Are Ready to Rebound "